Sentiment-Signal
25,4
Bearisch
Composite Score (0–100)
Insider (25%)
28.9
1 Insider, 3,3M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 30.01.2026 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 07.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ant to the Securities Act of 1933, as amended. Item 5.02 Departure of Directors or Certain Officers; Election of Direc |
| 28.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | mmon Stock or other securities of the Company. Item 5.02 Departure of Directors or Certain Officers; Election of Directo |
| 01.07.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | (a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 07.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ection 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 19.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
| 05.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointmen |
Stammdaten
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | Surrozen, Inc./DE |
|---|---|
| Ticker | SRZN |
| CIK | 0001824893 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 238,3 Mio. USD |
| Beta | 0,52 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 3,477,000 | -242,026,000 | -32.37 | 98,726,000 | -187,762,000 |
| 2025-09-30 | 10-Q | 983,000 | -71,643,000 | -8.36 | 94,046,000 | -23,515,000 |
| 2025-06-30 | 10-Q | 39,746,000 | 2.55 | 102,696,000 | 47,114,000 | |
| 2025-03-31 | 10-Q | -26,970,000 | -7.43 | 114,829,000 | 5,674,000 | |
| 2024-12-31 | 10-K | 10,655,000 | -63,564,000 | -21.67 | 48,467,000 | -21,380,000 |
| 2024-09-30 | 10-Q | 10,000,000 | -1,434,000 | -0.44 | 47,998,000 | 5,667,000 |
| 2024-06-30 | 10-Q | -25,261,000 | -7.99 | 45,071,000 | 6,062,000 | |
| 2024-03-31 | 10-Q | -8,830,000 | -4.24 | 36,716,000 | 30,136,000 | |
| 2023-12-31 | 10-K | 0 | -43,042,000 | -21.33 | 46,080,000 | 37,935,000 |
| 2023-09-30 | 10-Q | -10,445,000 | -5.14 | 53,973,000 | 45,531,000 | |
| 2023-06-30 | 10-Q | -9,387,000 | -4.68 | 63,999,000 | 55,058,000 | |
| 2023-03-31 | 10-Q | -14,297,000 | -7.16 | 74,200,000 | 63,037,000 | |
| 2022-12-31 | 10-K | -36,004,000 | -15.56 | 89,435,000 | 76,001,000 | |
| 2022-09-30 | 10-Q | -13,357,000 | -0.38 | 91,434,000 | 77,491,000 | |
| 2022-06-30 | 10-Q | -13,925,000 | -0.40 | 104,127,000 | 89,696,000 | |
| 2022-03-31 | 10-Q | -7,947,000 | -0.23 | 117,655,000 | 102,662,000 | |
| 2021-12-31 | 10-K | -54,648,000 | -2.21 | 137,174,000 | 109,700,000 | |
| 2021-09-30 | 10-Q | -14,019,000 | -0.51 | 150,636,000 | 123,731,000 | |
| 2021-06-30 | 10-Q | -12,653,000 | -0.69 | 92,946,625 | 22,822,000 | |
| 2021-03-31 | 10-Q | -13,022,000 | 93,435,668 | 34,852,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-24 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 53,329 | 24.69 | 1,316,858.33 | +504,3% | |
| 2026-03-23 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 7,612 | 24.90 | 189,538.04 | +72,6% | |
| 2026-03-23 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 7,611 | 24.90 | 189,513.14 | +72,6% | |
| 2026-03-16 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 595 | 24.99 | 14,866.49 | +5,7% | |
| 2026-03-13 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 17,717 | 24.88 | 440,744.04 | +168,8% | |
| 2026-03-13 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 17,716 | 24.88 | 440,719.16 | +168,8% | |
| 2026-03-12 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 6,187 | 24.99 | 154,582.81 | +59,2% | |
| 2026-02-12 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 547 | 23.86 | 13,052.79 | +5,0% | |
| 2026-02-12 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 546 | 23.86 | 13,028.93 | +5,0% | |
| 2026-02-11 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 8,882 | 23.58 | 209,393.15 | +80,2% | |
| 2026-02-11 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 8,881 | 23.58 | 209,369.58 | +80,2% | |
| 2026-02-03 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 2,178 | 21.94 | 47,785.32 | +18,3% | |
| 2026-02-03 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 2,177 | 21.94 | 47,763.38 | +18,3% | |
| 2026-02-02 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 365 | 21.38 | 7,803.70 | +3,0% | |
| 2026-02-02 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 366 | 21.38 | 7,825.08 | +3,0% | |
| 2026-01-30 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 2,135 | 21.39 | 45,667.65 | +17,5% | |
| 2026-01-30 | TCG Crossover GP II, LLC | 10% Owner | Open Market Purchase | 2,136 | 21.39 | 45,689.04 | +17,5% | |
| 2026-01-20 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 9,568 | 19.60 | 187,531.84 | +71,8% | |
| 2026-01-20 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 8,484 | 19.60 | 166,285.55 | +63,7% | |
| 2026-01-16 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 1,358 | 20.00 | 27,160.00 | +10,4% | |
| 2026-01-16 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 1,204 | 20.00 | 24,080.00 | +9,2% | |
| 2026-01-15 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 6,303 | 19.89 | 125,360.37 | +48,0% | |
| 2026-01-15 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 5,590 | 19.89 | 111,179.51 | +42,6% | |
| 2026-01-14 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 2,596 | 19.99 | 51,889.63 | +19,9% | |
| 2026-01-14 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 2,927 | 19.99 | 58,505.75 | +22,4% | |
| 2026-01-13 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 6,609 | 19.80 | 130,885.30 | +50,1% | |
| 2026-01-13 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 5,861 | 19.80 | 116,071.83 | +44,4% | |
| 2026-01-06 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 7,097 | 19.89 | 141,139.46 | +54,0% | |
| 2026-01-06 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 8,003 | 19.89 | 159,157.26 | +60,9% | |
| 2026-01-05 | Li Yang | Officer, Exec. Vice President, Research | Open Market Sale | -1,118 | 19.87 | -22,209.29 | -8,5% | |
| 2025-12-05 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 16,381 | 19.54 | 320,099.48 | +122,6% | |
| 2025-12-05 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 14,503 | 19.54 | 283,401.67 | +108,5% | |
| 2025-12-04 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 2,791 | 17.35 | 48,415.48 | +18,5% | |
| 2025-12-04 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 2,475 | 17.35 | 42,933.83 | +16,4% | |
| 2025-11-13 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 167,307 | 12.65 | 2,116,433.55 | +810,5% | |
| 2025-11-13 | COLUMN GROUP III GP, LP | 10% Owner | Open Market Purchase | 148,150 | 12.65 | 1,874,097.50 | +717,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.